Location History:
- Soka, JA (1976)
- Tokyo, JA (1976)
- Soka, JP (1980)
- Souka, JP (1980 - 1982)
Company Filing History:
7 out of 101 
1 out of 45 
1 out of 1 Years Active: 1976-1982
Title: Juichi Awaya: Innovator in Medicinal Chemistry
Introduction
Juichi Awaya is a prominent inventor based in Souka, Japan, known for his significant contributions to medicinal chemistry. With a total of 10 patents to his name, he has made remarkable advancements in the field of pharmaceuticals, particularly in the development of compounds that target infectious diseases.
Latest Patents
Among his latest patents are innovative compounds such as nanaomycin A and its derivatives. The invention relates to new compounds represented by a specific general formula, where R is H and R' is OH, identifying nanaomycin A. Another notable patent is for nanaomycin B, a quinone-type compound that exhibits activity against mycoplasma, Gram-positive bacteria, and trichophyton. This compound is particularly useful as a medicament for treating infectious diseases in both humans and animals. The acute toxicity of nanaomycin B, measured as LD50 via intra-peritoneal injection in mice, is 169 mg/Kg. The production of nanaomycin B involves fermentation using a nanaomycin-producing strain from the genus Streptomyces, cultured under aerobic conditions to recover the accumulated compound.
Career Highlights
Juichi Awaya has had a distinguished career, working with reputable organizations such as The Kitasato Institute and Kyowa Hakko Kogyo Co., Ltd. His work has significantly impacted the field of medicinal chemistry, leading to the development of effective therapeutic agents.
Collaborations
Throughout his career, Juichi Awaya has collaborated with notable scientists, including Satoshi Omura and Haruo Tanaka. These collaborations have further enriched his research and contributed to the advancement of his inventions.
Conclusion
Juichi Awaya's innovative work in the field of medicinal chemistry, particularly with compounds like nanaomycin A and B, showcases his dedication to addressing infectious diseases. His contributions continue to influence the pharmaceutical industry and improve health outcomes.